Related Experiment Videos
Mantle cell lymphoma: an update on management.
1Division of Hematologic Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA. A-Zelenetz@ski.mskcc.org
Summary
Rituximab with chemotherapy improves response rates but not survival. High-dose therapy improves outcomes, yet relapses persist, suggesting a need for novel treatments like radioimmunotherapy and targeted therapies.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Chemotherapy is a standard treatment for certain hematologic malignancies.
- Rituximab, a monoclonal antibody, is used in combination therapies.
- High-dose therapy with stem cell rescue is an established treatment modality.
Purpose of the Study:
- To evaluate the efficacy of rituximab in addition to induction chemotherapy.
- To compare high-dose therapy plus stem cell rescue with maintenance interferon alpha.
- To explore novel therapeutic strategies including radioimmunotherapy and targeted therapies.
Main Methods:
- Clinical trials comparing chemotherapy with and without rituximab.
- Studies assessing high-dose therapy and stem cell rescue versus interferon alpha maintenance.
- Evaluation of radioimmunotherapy and targeted therapies in preclinical or clinical settings.
Main Results:
- Rituximab increased response rates but did not improve progression-free or overall survival compared to chemotherapy alone.
- High-dose therapy plus stem cell rescue improved time to treatment failure and progression-free survival.
- Relapse rates did not plateau, indicating incomplete disease control.
- Radioimmunotherapy demonstrated single-agent activity; combination therapies are under investigation.
Conclusions:
- Current evidence does not support rituximab addition to induction chemotherapy for improved survival benefits.
- High-dose therapy offers survival advantages but does not eliminate relapse.
- Radioimmunotherapy and targeted therapies represent promising avenues for future treatment strategies, potentially in combination with existing modalities or transplantation.